Clinical & Experimental Cardiology
Open Access

Kristin Schmerbach

Publications

• Case Report
  Application of Ranolazine in Stable Angina Pectoris Therapy (ARETHA): Real-World Data from an Observational Study
  Author(s): Holger Diedrichs*, Ulrike Wollenberg, Kristin Schmerbach, Roger Limberg, Guido Schiffhorst, Andreas Michael Zeiher Holger Diedrichs*, Ulrike Wollenberg, Kristin Schmerbach, Roger Limberg, Guido Schiffhorst, Andreas Michael Zeiher
  
  Objective: Ranolazine, a late sodium current inhibitor, is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antiischaemic therapies. This study was conducted to assess the use of ranolazine as well as its safety and efficacy in patients with stable angina pectoris from different causes in a real world scenario. Methods: Patients with stable angina pectoris (AP) receiving ranolazine were enrolled in this non-interventional study. Data were documented at baseline and after 3 months of ranolazine treatment. Endpoints included changes in the number of AP attacks per week, frequency of using short-acting nitrates, current status of the CCS classification, overall estimate of quality of life assessed by both, the physician and the.. View More»
  DOI: 10.4172/2155-9880.1000412

  Abstract PDF

Relevant Topics